Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer. Phase 1

Abstract

Anti-PSMA designer T cells are autologous T cells that are gene-modified to express chimeric immunoglobulin-T cell receptors (lgTCR) that recognize the prostate specific membrane antigen. We will conduct a Phase I dose-escalation trial with infusion of designer T cells into prostate cancer patients after non- myeloablative (NMA) conditioning. This procedure will allow for the stable engraftment and persistence of the infused cells for improved therapeutic effect. The first year efforts have been in preparation of a clinical-grade vector producer cell (VPC) line, production and testing of clinical vector supernatants, and in harmonizing IRB-recommended protocol modifications and completing administrative features in advance of the trial. In year 2, the trial is planned to begin enrolling patients.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2006
Accession Number
ADA484801

Entities

People

  • Richar P. Junghans

Organizations

  • Roger Williams Medical Center

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biomedical Research
  • Blood
  • Cell Line
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Dilution
  • Gene Therapy
  • Health Services
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Production
  • Prostate
  • Prostate Cancer
  • Tissues

Fields of Study

  • Biology
  • Medicine

Readers

  • Clinical Trial Research.
  • Oncology (Cancer Research).